Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib + PD-1/PD-L1 Inhibitor in NSCLC
NCT06925048Phase 2Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ivarmacitinib in non-small cell lung cancer (NSCLC). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06925048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925048.